BIO vs. MTD, WAT, ILMN, TECH, CRL, BRKR, PACB, HBIO, LIFE, and TMO
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), aTyr Pharma (LIFE), and Thermo Fisher Scientific (TMO). These companies are all part of the "life sciences tools & services" industry.
Bio-Rad Laboratories (NYSE:BIO) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are held by institutional investors. 17.5% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 1.9% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.
Mettler-Toledo International received 3 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 64.82% of users gave Bio-Rad Laboratories an outperform vote while only 57.37% of users gave Mettler-Toledo International an outperform vote.
In the previous week, Mettler-Toledo International had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 12 mentions for Mettler-Toledo International and 6 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.17 beat Mettler-Toledo International's score of 0.74 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.
Bio-Rad Laboratories has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Bio-Rad Laboratories presently has a consensus target price of $436.67, indicating a potential upside of 52.37%. Mettler-Toledo International has a consensus target price of $1,256.25, indicating a potential downside of 12.39%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, equities research analysts clearly believe Bio-Rad Laboratories is more favorable than Mettler-Toledo International.
Mettler-Toledo International has a net margin of 20.55% compared to Bio-Rad Laboratories' net margin of -12.37%. Bio-Rad Laboratories' return on equity of 3.59% beat Mettler-Toledo International's return on equity.
Summary
Mettler-Toledo International beats Bio-Rad Laboratories on 11 of the 18 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Rad Laboratories Competitors List
Related Companies and Tools
